Although the number of patients diagnosed with synchronous multiple primary lung cancer is growing because of increased screening and improved imaging technology, synchronous triple primary lung cancer with different histological tumor subtypes occurring in the same lobe of the lung is extremely rare. In this report, we encountered a 64-year-old male patient with three different types of nodule in the right lower lobe of the lung found on chest computed tomography (CT) scan. We believed that the patient had triple primary lung cancer, and subsequently performed a right lower lobectomy using video-assisted thoracoscopic surgery (VATS). The pathological diagnosis was the same as the presurgical diagnosis, but all the nodules were different histological subtypes. To the best of our knowledge, this is the first case reported in the literature of synchronous triple primary lung cancer with three different histological subtypes in the same lobe of the lung. KEY POINTS SIGNIFICANT FINDINGS OF THE STUDY This is the first case of synchronous triple primary lung cancer with three different histological subtypes in each tumor in the same lobe of the lung. WHAT THIS STUDY ADDS We report the details of the case with immunohistochemical and gene mutation findings, and a literature review of synchronous primary lung cancer.In this work, the core-shelled Sb@Sb2 O3 heterostructure encapsulated in 3D N-doped carbon hollow-spheres is fabricated by spray-drying combined with heat treatment. The novel core-shelled heterostructures of Sb@Sb2 O3 possess a mass of heterointerfaces, which formed spontaneously at the core-shell contact via annealing oxidation and can promote the rapid Na+ /K+ transfer. The density functional theory calculations revealed the mechanism and significance of Na/K-storage for the core-shelled Sb@Sb2 O3 heterostructure, which validated that the coupling between the high-conductivity of Sb and the stability of Sb2 O3 can relieve the shortcomings of the individual building blocks, thereby enhancing the Na/K-storage capacity. Furthermore, the core-shell structure embedded in the 3D carbon framework with robust structure can further increase the electrode mechanical strength and thus buffer the severe volume changes upon cycling. As a result, such composite architecture exhibited a high specific capacity of ≈573 mA h g-1 for sodium-ion battery (SIB) anode and ≈474 mA h g-1 for potassium-ion battery (PIB) anode at 100 mA g-1 , and superior rate performance (302 mA h g-1 at 30 A g-1 for SIB anode, while 239 mA h g-1 at 5 A g-1 for PIB anode).Cystic fibrosis (CF) patients utilize an average of 10 (±5) medications per day. Given the complexity of the medication regimen, the CF Foundation (CFF) recommends pharmacists as members of the CF care team. The areas of pharmacy services have been identified in the literature. "Limited access pharmacists" are consulted to answer questions, assist in evaluating serum drug concentrations, provide medication education, and monitor for drug-drug interactions. Reduction in hospital length of stay has been shown through this collaboration. "Full access pharmacists" provide comprehensive medication therapy management resulting in medication adherence and access improvements, sustainability of treatments, improved provider communication, reduced medication errors and costs, expedited medication refill authorization, increased utilization of respiratory therapists, enhanced discussion of medications with CF team members, and reduction in the number of pharmacies utilized by patients to fill CF medications. An integrated CF pharmacy team are essential members of the multidisciplinary CF care team that have been shown to improve in CF medication access, increases in body weight and body mass index, reduction in prior authorization submission times, reduction in medication delivery times, expedited medication refill authorizations, increased collaboration with respiratory therapists, augmented discussion of medication with CF team members, and reduction in the number of pharmacies utilized by CF patients. There is a need to further evaluate the impact of outpatient CF pharmacy services due to the improvements in the care on patients and families affected by CF, and as the number of CFF-accredited care centers integrates CF pharmacy teams throughout the country increases.In spite of the successful use of monoclonal antibodies (mAbs) in clinic for tumor treatment, their applications are still hampered in therapeutic development due to limitations, such as tumor penetration and high cost of manufacture. Nanobody, a single domain antibody that holds the strong antigen targeting and binding capacity, has demonstrated various advantages relative to antibody. Nanobody is considered as a next-generation of antibody-derived tool in the antigen related recognition and modulation. A number of nanobodies have been developed and evaluated in different stages of clinical trials for cancer treatment. Here we summarized the current progress of nanobody in tumor diagnosis and therapeutics, particularly on the conjugation of nanobody with functional moieties. The nanobody conjugation of diagnostic agents, such as radionuclide and optical tracers, can achieve specific tumor imaging. The nanobody-drug conjugates can enhance the therapeutic efficacy of anti-tumor drugs and reduce the adverse effects. The decoration of nanobody on nanodrug delivery systems can further improve the drug targeting to specific tumors.  https://www.selleckchem.com/products/cc-122.html  This article is categorized under Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
  Glutathione S-transferase (GST) gene deletion or polymorphic sequence variations lead to decreased enzyme activity that influences susceptibility and response to tyrosine kinase inhibitors in chronic myeloid leukemia (CML). We aimed to analyze relation of different GST gene sequence variants with susceptibility and response to Imatinib in CML.
 
  A total of 150CML cases and equal number of age and gender matched healthy controls were genotyped for five GST polymorphisms by multiplex-PCR and PCR-RFLP techniques. BCR-ABL1 transcripts were quantified by quantitative Real Time PCR (qRT-PCR).
 
  GSTT1, GSTO1, and GSTO2 SNPs revealed no association, while as GSTM1
  genotype was observed to protect against the development of CML (OR=0.53, P=.01). GSTP1 variant genotypes AG (OR=2.1, P=.003) and GG (OR=5.6, P<.001), significantly associated with increased risk of CML. Combined genotype analysis showed protective impact of GSTT1
  /GSTM1
  (OR=0.44, P=.003) while as GSTT1
  /GSTP1-GG (OR=6.92, P<.001) and GSTM1
  /GSTP1-GG (OR=6.